期刊文献+

类风湿关节炎治疗达标率的影响因素 被引量:1

Study on influencing factors of the success rate of treatment for rheumatoid arthritis
下载PDF
导出
摘要 目的:基于智能疾病管理系统分析影响类风湿关节炎治疗达标的因素,为进一步调整慢性病管理策略提供参考。方法:回顾性分析2018年1月—2020年12月在重庆市某三级甲等医院风湿病科接受慢性病管理的471例类风湿关节炎病人,根据是否达标分为达标组和未达标组,收集性别、年龄、病程、是否因药物副作用调整方案、是否规律用药、是否有经济负担、是否受其他疾病影响、是否受行动不便或路途远影响、是否定期复诊等资料,并分析其影响因素。结果:基于智能疾病管理系统对类风湿关节炎病人进行慢性病管理总达标率为57.3%,不同年龄、规律用药、定期复诊病人类风湿关节炎病人治疗达标率不同(P<0.05)。结论:应加强对老年病人的关怀,提高老年病人的依从性,指导病人规律用药和定期复诊有利于提高类风湿关节炎病人治疗的达标率。
作者 田颖 谢华灵 吴斌 张莹 TIAN Ying;XIE Hualing;WU Bin;ZHANG Ying(Chongqing Traditional Chinese Medicine Hospital,Chongqing 400021 China)
机构地区 重庆市中医院
出处 《护理研究》 北大核心 2024年第3期549-551,共3页 Chinese Nursing Research
关键词 慢性病 类风湿关节炎 达标治疗 影响因素 智能疾病管理系统 chronic disease rheumatoid arthritis treatment up to standard influence factor intelligent disease management system
  • 相关文献

参考文献14

二级参考文献161

  • 1中华人民共和国卫生部.卫生部关于印发《国家基本公共卫生服务规范(2011年版)》的通知[EB/OL].(2011-04-25)[2012-02-03].http://www.moh.gov.cn/mohfybjysqwss/s3577/201105/51780.shtml.
  • 2Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Com- mittee. Treating rheumatoid arthritis to target: recommendations of an international task force[J]. Ann Rheum Dis, 2010, 69: 631-637.
  • 3Smolen JS, Landewe R, Breodveld FC, et al. EULAR recom- mendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs[J]. Ann Rheum Dis, 2010, 69: 964-975.
  • 4Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a recta-analysis [J]. Lancet, 2001, 358: 1305-1315.
  • 5Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Asso- ciation for the Study of Diabetes (EASD)[J]. Eur Heart J, 2007, 28: 88-136.
  • 6Smolen JS, Aletaha D, Keystone E. Superior efficacy of com- bination therapy for rheumatoid arthritis: fact or fiction? [J]. Arthritis Rheum, 2005, 52: 2975-2983.
  • 7Goekoop-Ruiterman Yp, de Vries-Bouwstra JK, Allaart CF, ct al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial [J]. Arthritis Rheum, 2005, 52: 3381-3390.
  • 8Costenbader KH, Feskanich D, Mandl LA, et al. Smoking in- tensity, duration, and cessation, and the risk of rheumatoid arthritis in women[J]. Am J Med, 2006, 119: 503. e1-9.
  • 9Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on dis- ease activity and joint damage in early rheumatoid arthritis [J]. Rheumatology (Oxford), 2006, 45: 734-740.
  • 10Westhoff G, Ran R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group [J]. Rheumatology (Oxford), 2008, 47: 849- 854.

共引文献399

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部